Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin
Corbin KD, Dagogo-Jack S, Cannon CP, et al.
Diabetes Obes Metab. 2023;25(3):758-766.
Leggi